Big Pharma Turns to China for Innovative Drug Development
Major Western pharmaceutical companies are increasingly turning to China's biotechnology sector to source innovative drug candidates, marking a significant shift in the global industry landscape. Historically viewed as a manufacturer of generic drugs and ingredients, China has rapidly evolved into a leader in cutting-edge molecular biology and biotech research. A prime example is Pfizer, which recently paid $1.25 billion to Chinese firm 3SBio for rights to a promising cancer drug candidate. This strategic move highlights how China's biotechs are leveraging faster development cycles and lower costs to compete with and potentially overtake Western counterparts. Pfizer CEO Albert Bourla noted the unprecedented level of innovation emerging from China, particularly in treatments for cancer and weight-loss diseases. The article illustrates this trend through the lens of GluBio, a San Diego-based company, while emphasizing that China is no longer just a market for selling Western medicines but a primary source of new medical ideas. This transition underscores the growing competitiveness of Chinese startups in developing hot new medicines, challenging the traditional dominance of Western pharmaceutical research and reshaping international partnerships in the healthcare sector.
Wire timeline
Big Pharma Turns to China for Innovative Drug Development
Major Western pharmaceutical companies are increasingly turning to China's biotechnology sector to source innovative drug candidates, marking a significant shift in the global industry landscape. Historically viewed as a manufacturer of generic drugs and ingredients, China has rapidly evolved into a leader in cutting-edge molecular biology and biotech research. A prime example is Pfizer, which recently paid $1.25 billion to Chinese firm 3SBio for rights to a promising cancer drug candidate. This strategic move highlights how China's biotechs are leveraging faster development cycles and lower costs to compete with and potentially overtake Western counterparts. Pfizer CEO Albert Bourla noted the unprecedented level of innovation emerging from China, particularly in treatments for cancer and weight-loss diseases. The article illustrates this trend through the lens of GluBio, a San Diego-based company, while emphasizing that China is no longer just a market for selling Western medicines but a primary source of new medical ideas. This transition underscores the growing competitiveness of Chinese startups in developing hot new medicines, challenging the traditional dominance of Western pharmaceutical research and reshaping international partnerships in the healthcare sector.
Technology - WSJ.com